Belgium Hosts 38 ATMP Companies — But Most Still Fail to Commercialize

Belgium is not early anymore.

• 38+ ATMP companies in Wallonia alone
• 21 companies already mapped across a single ATMP portfolio
• One of Europe’s densest clinical + manufacturing ecosystems

And yet…

👉 Most cell & gene therapy companies still struggle to:

• Move beyond clinical proof
• Navigate manufacturing scale
• Align with payer and procurement pathways
• Convert innovation into predictable revenue

Because this is not a science problem anymore.

It’s a commercialization stack problem.

⚠️ THE REAL GAP: BELGIUM HAS INFRASTRUCTURE — NOT ORCHESTRATION

Belgium has everything:

• World-class therapy builders
• Deep platform and research infrastructure
• Strong GMP manufacturing backbone
• Elite clinical trial institutions
• Active policy and cluster ecosystem

But these layers are still fragmented in execution.

👉 The winners are not the best technologies.
👉 The winners are the companies that orchestrate across the stack.

🧩 THE BELGIUM CELL & GENE THERAPY COMMERCIALIZATION STACK

1. Therapy Builders

(Where value starts — but rarely where scale happens)

These are the companies creating actual CGT products.

• eTheRNA immunotherapies
• Coave Therapeutics
• Novadip Biosciences
• Promethera Biosciences / Cellaïon
• Genflow Biosciences
• convEyXO
• Epitopoietic Research Corporation
• AstriVax Therapeutics
• Precigen ActoBio
• myNEO Therapeutics
• Legend Biotech
• Johnson & Johnson Innovative Medicine Belgium
• Galapagos
• Ziphius Therapeutics
• Quantoom Biosciences
• Augustine Therapeutics
• ExeVir Bio
• UCB

🔍 Key Insight:

Most of these companies are clinical-first, not commercialization-first.

They optimize for:

• Clinical endpoints
• Scientific novelty

But underinvest in:

• Workflow integration
• Reimbursement strategy
• Manufacturing economics

👉 Result: strong pipelines, weak market entry

2. Platform Enablers

(Where scalability is engineered)

These players make therapies repeatable, scalable, and investable.

• Antleron
• MyCellHub
• N-SIDE
• CellCarta
• Eurogentec
• Trince
• Agilytic
• FlandersBio
• BioWin
• MEDVIA
• BioVille
• BioPark Charleroi
• LégiaPark
• VIB
• VITO
• imec
• Confo Therapeutics
• AdBio Partners

🔍 Key Insight:

This layer is Belgium’s unfair advantage.

But most founders:

• Treat platforms as vendors
• Not as core commercialization infrastructure

👉 The shift:
Platform-first thinking = faster scale + lower burn + higher valuation

3. GMP Operators

(Where most companies break)

Manufacturing is the #1 bottleneck in CGT commercialization.

• Exothera
• Cellistic
• Eurofins Biopharma Product Testing Belgium
• Quality Assistance
• Catalent Belgium
• Ajinomoto Omnichem
• SGS Health Science
• Ardena
• Cryoport Systems
• World Courier
• CRYOPDP
• Brussels Airport Pharma Hub
• Yposkesi
• ViroCell Biologics
• HALIX
• Batavia Biosciences
• AGC Biologics Heidelberg
• Lonza

🔍 Key Insight:

Most companies approach GMP too late.

They think:
👉 “We’ll solve manufacturing after Phase II”

Reality:
👉 Manufacturing defines:

• Cost per treatment
• Margin structure
• Scalability ceiling

👉 If you don’t design for GMP early, you price yourself out of the market later

4. Trial Anchors

(Where validation happens — but also where delays compound)

• Ghent University Hospital
• KU Leuven
• UZ Leuven
• Linx Leuven
• Vrije Universiteit Brussel
• UCLouvain
• ULiège
• University of Antwerp
• Institut Jules Bordet
• Sciensano
• Saint-Luc University Clinics
• UZ Brussel

• cross-border clinical nodes (e.g., Greece hospital networks)

🔍 Key Insight:

Belgium is a clinical execution powerhouse.

But:

👉 Clinical success ≠ commercial readiness

Most founders fail to:

• Design trials aligned with payer expectations
• Capture real-world evidence early
• Build procurement narratives alongside trials

5. Market Connectors

(Where commercialization actually happens — or fails)

• pharma.be
• beMedTech
• Flanders Investment & Trade
• AWEX
• BioWin
• MEDVIA
• flanders.bio
• Essenscia
• Federal Agency for Medicines and Health Products
• European Medicines Agency
• Alliance for Regenerative Medicine
• EIT Health Belgium-Netherlands

🔍 Key Insight:

This layer controls:

• Policy
• Reimbursement pathways
• Market access
• Strategic partnerships

Yet most startups engage too late.

👉 By the time they talk to this layer:

• Pricing is already misaligned
• Evidence is insufficient
• GTM strategy is reactive

⚙️ THE REAL SYSTEM: HOW WINNING CGT COMPANIES SCALE IN BELGIUM

The companies that win follow a 5-layer orchestration model:

1. Clinical + commercial co-design

→ Trials designed for payer + provider adoption

2. GMP-first architecture

→ Manufacturing built into early strategy

3. Platform integration early

→ Not post-hoc

4. Market access parallelization

→ Not after approval

5. Ecosystem leverage

→ Clusters, regulators, and partners activated early

📉 WHY MOST CGT STARTUPS FAIL IN THIS ECOSYSTEM

Even in Belgium — one of Europe’s strongest ecosystems — failure patterns are consistent:

• Over-index on science, under-index on commercialization
• Treat ecosystem players as optional, not strategic
• Delay GMP and pricing logic
• Ignore procurement pathways until too late
• Lack orchestration across layers

👉 Result:
Brilliant therapies that never scale commercially

🚀 WHERE I COME IN (THE MISSING LAYER)

This is exactly the gap GrowthVybz is built to solve.

Not more:

• Strategy decks
• Generic market research

But:
👉 Commercialization system design

I help founders:

• Align clinical, regulatory, and GTM strategy
• Design payer-ready evidence pathways
• Structure GMP + pricing logic early
• Build investor-grade commercialization narratives
• Turn ecosystems like Belgium into scalable revenue systems

👉 Because in CGT:
Science gets you validated.
Commercialization gets you funded and scaled.

📌 FINAL TAKEAWAY

Belgium is not lacking infrastructure.

It’s lacking orchestration discipline.

And that’s where the next generation of winners will emerge.